Sponsor

Clinical trials sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Active studies whose public registry record names Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. as lead sponsor.

12active studies

5recruiting now

1countries represented

1largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

ObesityCondition

HDM1005 dose level 1, HDM1005 dose level 2Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-04-13 · NCT07521631See eligibility →

Recruiting nowPhase 1

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Overweight Subject, Healthy SubjectsCondition

Metformin, EmpagliflozinTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-01-09 · NCT07331389See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

Obesity & OverweightCondition

HDM1005 1, HDM1005 2Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-12-12 · NCT07279194See eligibility →

Recruiting nowPhase 2

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

ObesityCondition

HDM1005 injection or placeboTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-09-30 · NCT06886126See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Obesity ControlCondition

HDM1702, Wegovy ®Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-06-25 · NCT07036172See eligibility →

Opening soonPhase 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy

Obstructive Sleep Apnea (OSA) and ObesityCondition

HDM1005, PlaceboTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07794397See eligibility →

Opening soonPhase 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

Obstructive Sleep Apnea (OSA) and ObesityCondition

HDM1005, PlaceboTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-08-26 · NCT07787260See eligibility →

Opening soonPhase 1

A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

Overweight, ObeseCondition

HDM1005Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-05-08 · NCT07559240See eligibility →

Opening soonPhase 1

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

Overweight, ObesityCondition

Acetaminophen, MetforminTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-03-30 · NCT07502001See eligibility →

Opening soonPhase 3

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Type 2 DiabetesCondition

HDM1005 1, HDM1005 2Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-02-18 · NCT07417306See eligibility →

Opening soonPhase 3

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Overweight and ObesityCondition

HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral, once daily, 52 weeksTreatment

Locations pending0 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-03-19 · NCT06885021See eligibility →

Opening soonPhase 1

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Healthy Adult Subject, Overweight SubjectCondition

Repaglinide, AtorvastatinTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2024-09-23 · NCT06601517See eligibility →

Related sponsors

Novo Nordisk A/S71 Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.